Business
IceCure Medical Ordinary Shares to Trade Exclusively on Nasdaq: Company to Voluntarily Delist Shares from Trading on the Tel Aviv Stock Exchange
CAESAREA, Israel , April 19, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of
About this update from Icecure Medical Ltd.
[{"type":"text","content":"CAESAREA, Israel , April 19, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) (\"IceCure\" or the \"Company\"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announces that it has initiated a process to voluntarily delist its ordinary shares, no par value per share (the \"Ordinary Shares\"), from the Tel Aviv Stock Exchange (the \"TASE\").\n \nIn accordance with applicable Israeli law and the rules of the TASE, the last day the Ordinary Shares will trade on the TASE will be July 20, 2023 and the Ordinary Shares will be delisted from the TASE on July 24, 2023. Until the last day of trading on the TASE, shareholders will be able to continue to buy and sell Ordinary Shares in the same manner as has been the case to date.\nThe Company's Ordinary Shares will continue to be traded on the Nasdaq Capital Market (\"Nasdaq\") under the symbol \"ICCM,\" and the Company will continue to file public reports and make public disclosures in accordance with the rules of the U.S. Securities and Exchange Commission (the \"SEC\") and Nasdaq. The delisting in Israel will not affect the Company's continued listing on Nasdaq in the United States and all Ordinary Shares now traded on the TASE may be transferred to Nasdaq.\n\"We believe it is in the best interest of the company and its shareholders to focus on our efforts in the U.S. capital markets with our Ordinary Shares trading exclusively on Nasdaq,\" said Ron Mayron, Chairman of the Board of Directors. \"From an operational, developmental, and strategic perspective, Israel remains of vital importance to IceCure, while delisting from the TASE will reduce redundant listing costs. This decision underscores our commitment to our U.S. investors and to the U.S. healthcare market, where we believe our unique cryoablation technologies have the greatest potential to provide physicians with medical solutions that achieve enhanced patient outcomes and, as a result, will potentially build shareholder value. We value all our TASE investors and thank them for their ongoing support.\"\nAbout IceCure Medical Ltd.\nIceCure Medical (Nasdaq: ICCM) (TASE: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign...